This story has been updated from a previous version that incorrectly stated the development status of an Alynlam AHP drug candidate.

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals announced on Thursday that it has expanded a program that provides no-cost genetic testing for people at risk for certain genetic diseases to include acute hepatic porphyrias (AHPs).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.